Q1 Revenue Jumps 11% to $230M; Telix Reaffirms Guidance, Advances Key Drug Pipeline
Summary
Telix Pharmaceuticals reported strong Q1 2026 unaudited group revenue of US$230 million, marking an 11% increase quarter-over-quarter, and reaffirmed its full-year 2026 revenue guidance of US$950 million to US$970 million. This robust financial performance was complemented by significant advancements across its therapeutics pipeline. Key milestones include positive safety and dosimetry objectives met in Part 1 of the ProstACT Global Phase 3 study for its lead prostate cancer therapy candidate, TLX591-Tx, with no new safety signals observed. Additionally, the company resubmitted a New Drug Application (NDA) to the FDA for its brain cancer imaging candidate TLX101-Px, filed a Marketing Authorization Application (MAA) in Europe for Pixlumi, and had an NDA accepted in China for TLX591-Px. These developments indicate strong commercial execution and substantial progress in de-risking and advancing its product portfolio, providing multiple future growth catalysts. Investors will be watching for continued progress in the randomized treatment expansion of ProstACT Global and further regulatory approvals.
At the time of this announcement, TLX was trading at $9.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $6.28 to $20.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.